SCHEMBL2205486

SCHEMBL2205486

O=C1C(Cc2c(Cl)cc(O)cc2Cl)CCN1C1CCc2cn[nH]c2C1

nearest known ligand 0.31

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.31
LMNA P02545 2/20 0.31
CYP19A1 P11511 1/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
ADRB2 P07550 1/20 0.31
THRB P10828 1/20 0.31
DRD2 P14416 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
DRD1 P21728 1/20 0.31
DRD4 P21917 1/20 0.31
HTR2A P28223 1/20 0.31
CYP2C19 P33261 1/20 0.31
DRD3 P35462 1/20 0.31
GRM5 P41594 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CYP26A1 O43174 1/20 0.31
BLM P54132 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2205483 1.00 HSD11B1 (0.31) HSD11B1LMNACYP19A1MEN1CYP1A2
SCHEMBL2205480 1.00 HSD11B1 (0.31) HSD11B1LMNACYP19A1MEN1CYP1A2
SCHEMBL2208431 0.86 ROCK2 (0.38) HSD11B1DRD2HTR2AF2F10
SCHEMBL2208439 0.86 ROCK2 (0.38) HSD11B1DRD2HTR2AF2F10
SCHEMBL2208435 0.86 ROCK2 (0.38) HSD11B1DRD2HTR2AF2F10
SCHEMBL2207838 0.84 HSD11B1 (0.38) HSD11B1
SCHEMBL3454689 0.83 ADRA1A (0.37) HSD11B1
SCHEMBL3453433 0.83 ADRA1A (0.37) HSD11B1
SCHEMBL3453429 0.83 ADRA1A (0.37) HSD11B1
SCHEMBL3453426 0.80 ADRA1A (0.32) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029579-B1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2014-12-31 EP disclosed
US-7981918-B2 Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-07-19 US disclosed
US-20090111800-A1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-30 US disclosed
EP-2029579-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
WO-2007124254-A2 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111800-A1 CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD3B1, HSD17B1 HSD11B1 1/4885LMNA 1959/4885CYP19A1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.